Machine Learning Advances Fight Against Cancer

By John Russell

May 18, 2016

Developing effective tools against cancer has been a long, complicated endeavor with successes and disappointments. Despite all, cancer remains the leading cause of death worldwide. Now, machine learning and data analytics are being recruited as tools in the effort fight the disease and show significant promise according to two recent papers.

In one paper – An Analytics Approach to Designing Combination Chemotherapy Regimens for Cancer – researchers from MIT and Stanford “propose models that use machine learning and optimization to suggest regimens to be tested in phase II and phase III trials.” Their work, published in March in Management Science, could help cut costs and speed clinical trials. Importantly, it and focuses on combination therapy, perhaps the toughest to model but which has proven the more effective for most cancers.

The second study, by researchers from Regenstrief Institute and Indiana University School of Informatics and Computing, found that existing algorithms and open source machine learning tools were as good or better than human reviewers in detecting cancer cases using data from free-text pathology reports. Moreover, the computerized approach was faster and less resource intensive in comparison to human counterparts.

This latter study – Towards Better Public Health Reporting Using Existing Off the Shelf Approaches: A Comparison of Alternative Cancer Detection Approaches Using Plaintext Medical Data and Non-dictionary Based Feature Selection – was published last month in Journal of Biomedical Informatics.

The cancer challenge, of course, isn’t new. Cancer kills roughly nine million people each year. While advancing genomics and molecular medicine have made great strides in revealing many of cancer’s underlying causes and proven effective in many cases, definitive cures have remained mostly elusive. One reason is simply there are so many cancers; another is even a single tumor may have many different mutations, each sensitive to a different therapy.

It now turns out that machine learning and analytics may well prove to be especially valuable in approaching cancer drug development and therapy selections. Data mining has certainly been applied before but the confluence of appropriate technologies (analytics and compute) along with sufficient quantities of clinical data and outcomes data are key enablers.

In the first study the focus was on gastric cancer. The authors note that individualized predictions, using their methods, represent a useful tool to patients choosing between multiple treatment options and, when trained on clinical trial outcomes for a particular treatment, can be used to identify promising patient populations on which to test that treatment or to determine if that treatment is promising for a phase III clinical trial. The MIT-Stanford team emphasizes what they think are three “major contributions” their work provides, excerpted below:

  • “Clinical Trial Database. We developed a database containing information about the patient demographics, study characteristics, chemotherapy regimens tested, and outcomes of all phase II and phase III clinical trials for advanced gastric cancer from papers published in the period 1979–2012. Surprisingly, and to the best of our knowledge, such a database did not exist before this study.
  • “Statistical Models Predicting Clinical Trial Outcomes. We train statistical models using the results of previous randomized and nonrandomized clinical trials. We use these models to predict survival and toxicity outcomes of new clinical trials evaluating regimens whose drugs have individually been tested before, but potentially in different combinations or dosages. To our knowledge, this is the first paper to employ statistical models for the prediction of clinical trial outcomes of arbitrary drug combinations and to perform an out-of-sample evaluation of the predictions.
  • “Design of Chemotherapy Regimens. We propose and evaluate tools for suggesting novel chemotherapy regimens to be tested in phase II studies and for selecting previously tested regimens to be further evaluated in phase III clinical trials. Our methodology balances the dual objectives of exploring novel chemotherapy regimens and testing treatments predicted to be highly effective. To our knowledge, this is the first use of statistical models and optimization to design novel chemotherapy regimens based on the results of previous clinical trials.”

The authors note it is inherently challenging to evaluate the performance of their models without actually running clinical trials and they use two techniques to obtain estimates for the quality of regimens selected by their models compared with those actually tested in current clinical practice. “Both techniques indicate that the models might improve the efficacy of the regimens selected for testing in phase III clinical trials without changing toxicity outcomes,” they write. “This evaluation of the proposed models suggests that they merit further testing in a clinical trial setting.”

Cancer Figure

Their study should be read in full as the authors present their methods in detail and their assessment of varying approaches. Listed authors include: Dimitris Bertsimas, Sloan School and Operations Research Center, MIT; Allison O’Hair, Stanford Graduate School of Business; Stephen Relyea, Lincoln Laboratory, MIT; and John Silberholz, Sloan School and Operations Research Center, MIT.

In the second study, researchers found the commonly used algorithms equaled or exceed pathologists in detecting cancer.

“We think that its no longer necessary for humans to spend time reviewing text reports to determine if cancer is present or not,” said study senior author Shaun Grannis, interim director of the Regenstrief Center of Biomedical Informatics. “We have come to the point in time that technology can handle this. A human’s time is better spent helping other humans by providing them with better clinical care.”

“A lot of the work that we will be doing in informatics in the next few years will be focused on how we can benefit from machine learning and artificial intelligence. Everything – physician practices, health care systems, health information exchanges, insurers, as well as public health departments – are awash in oceans of data. How can we hope to make sense of this deluge of data? Humans can’t do it – but computers can.”

The researchers sampled 7,000 free-text pathology reports from over 30 hospitals that participate in the Indiana Health Information Exchange and used open source tools, classification algorithms, and varying feature selection approaches to predict if a report was positive or negative for cancer. The results indicated that a fully automated review yielded results similar or better than those of trained human reviewers, saving both time and money.

The study evaluated the capacity to detect cancer cases from the reports using three non-dictionary feature selection approaches, four feature subset sizes, and five clinical decision models: simple logistic regression, naive bayes, k-nearest neighbor, random forest, and J48 decision tree. The performance of each decision model was evaluated using sensitivity, specificity, accuracy, positive predictive value, and area under the receiver operating characteristics (ROC) curve.

Shaun Grannis
Shaun Grannis

“Machine learning can now support ideas and concepts that we have been aware of for decades, such as a basic understanding of medical terms,” said Grannis. “We found that artificial intelligence was as least as accurate as humans in identifying cancer cases from free-text clinical data. For example the computer ‘learned’ that the word ‘sheet’ or ‘sheets’ signified cancer as ‘sheet’ or ‘sheets of cells’ are used in pathology reports to indicate malignancy.

Grannis emphasized the team’s work “is not an advance in ideas, it’s a major infrastructure advance — we have the technology, we have the data, we have the software from which we saw accurate, rapid review of vast amounts of data without human oversight or supervision.”

The study was conducted with support from the Centers for Disease Control and Prevention. In addition to Grannis, co-authors of the study are Brian E. Dixon (Regenstrief Institute), Huiping Xu (IU Fairbanks School of Public Health), Judy Gichoya (Regenstrief Institute), Burke Mamlin (IU School of Medicine), Yuni Xian (School of Science, IUPUI), and Suranga N. Kasthurirathne (a doctoral student at School of Informatics and Computing at IUPUI).

Link to first paper discussed, An Analytics Approach to Designing Combination Chemotherapy Regimens for Cancer, http://www.mit.edu/~dbertsim/papers/HealthCare/An%20Analytics%20Approach%20to%20Designing%20Clinical%20Trials%20for%20Cancer.pdf

Link to second paper discussed, Towards Better Public Health Reporting Using Existing Off the Shelf Approaches: A Comparison of Alternative Cancer Detection Approaches Using Plaintext Medical Data and Non-dictionary Based Feature Selection, published in Journal of Biomedical Informatics, http://www.sciencedirect.com/science/article/pii/S1532046416000095

Subscribe to HPCwire's Weekly Update!

Be the most informed person in the room! Stay ahead of the tech trends with industry updates delivered to you every week!

MLPerf Inference 4.0 Results Showcase GenAI; Nvidia Still Dominates

March 28, 2024

There were no startling surprises in the latest MLPerf Inference benchmark (4.0) results released yesterday. Two new workloads — Llama 2 and Stable Diffusion XL — were added to the benchmark suite as MLPerf continues Read more…

Q&A with Nvidia’s Chief of DGX Systems on the DGX-GB200 Rack-scale System

March 27, 2024

Pictures of Nvidia's new flagship mega-server, the DGX GB200, on the GTC show floor got favorable reactions on social media for the sheer amount of computing power it brings to artificial intelligence.  Nvidia's DGX Read more…

Call for Participation in Workshop on Potential NSF CISE Quantum Initiative

March 26, 2024

Editor’s Note: Next month there will be a workshop to discuss what a quantum initiative led by NSF’s Computer, Information Science and Engineering (CISE) directorate could entail. The details are posted below in a Ca Read more…

Waseda U. Researchers Reports New Quantum Algorithm for Speeding Optimization

March 25, 2024

Optimization problems cover a wide range of applications and are often cited as good candidates for quantum computing. However, the execution time for constrained combinatorial optimization applications on quantum device Read more…

NVLink: Faster Interconnects and Switches to Help Relieve Data Bottlenecks

March 25, 2024

Nvidia’s new Blackwell architecture may have stolen the show this week at the GPU Technology Conference in San Jose, California. But an emerging bottleneck at the network layer threatens to make bigger and brawnier pro Read more…

Who is David Blackwell?

March 22, 2024

During GTC24, co-founder and president of NVIDIA Jensen Huang unveiled the Blackwell GPU. This GPU itself is heavily optimized for AI work, boasting 192GB of HBM3E memory as well as the the ability to train 1 trillion pa Read more…

MLPerf Inference 4.0 Results Showcase GenAI; Nvidia Still Dominates

March 28, 2024

There were no startling surprises in the latest MLPerf Inference benchmark (4.0) results released yesterday. Two new workloads — Llama 2 and Stable Diffusion Read more…

Q&A with Nvidia’s Chief of DGX Systems on the DGX-GB200 Rack-scale System

March 27, 2024

Pictures of Nvidia's new flagship mega-server, the DGX GB200, on the GTC show floor got favorable reactions on social media for the sheer amount of computing po Read more…

NVLink: Faster Interconnects and Switches to Help Relieve Data Bottlenecks

March 25, 2024

Nvidia’s new Blackwell architecture may have stolen the show this week at the GPU Technology Conference in San Jose, California. But an emerging bottleneck at Read more…

Who is David Blackwell?

March 22, 2024

During GTC24, co-founder and president of NVIDIA Jensen Huang unveiled the Blackwell GPU. This GPU itself is heavily optimized for AI work, boasting 192GB of HB Read more…

Nvidia Looks to Accelerate GenAI Adoption with NIM

March 19, 2024

Today at the GPU Technology Conference, Nvidia launched a new offering aimed at helping customers quickly deploy their generative AI applications in a secure, s Read more…

The Generative AI Future Is Now, Nvidia’s Huang Says

March 19, 2024

We are in the early days of a transformative shift in how business gets done thanks to the advent of generative AI, according to Nvidia CEO and cofounder Jensen Read more…

Nvidia’s New Blackwell GPU Can Train AI Models with Trillions of Parameters

March 18, 2024

Nvidia's latest and fastest GPU, codenamed Blackwell, is here and will underpin the company's AI plans this year. The chip offers performance improvements from Read more…

Nvidia Showcases Quantum Cloud, Expanding Quantum Portfolio at GTC24

March 18, 2024

Nvidia’s barrage of quantum news at GTC24 this week includes new products, signature collaborations, and a new Nvidia Quantum Cloud for quantum developers. Wh Read more…

Alibaba Shuts Down its Quantum Computing Effort

November 30, 2023

In case you missed it, China’s e-commerce giant Alibaba has shut down its quantum computing research effort. It’s not entirely clear what drove the change. Read more…

Nvidia H100: Are 550,000 GPUs Enough for This Year?

August 17, 2023

The GPU Squeeze continues to place a premium on Nvidia H100 GPUs. In a recent Financial Times article, Nvidia reports that it expects to ship 550,000 of its lat Read more…

Shutterstock 1285747942

AMD’s Horsepower-packed MI300X GPU Beats Nvidia’s Upcoming H200

December 7, 2023

AMD and Nvidia are locked in an AI performance battle – much like the gaming GPU performance clash the companies have waged for decades. AMD has claimed it Read more…

DoD Takes a Long View of Quantum Computing

December 19, 2023

Given the large sums tied to expensive weapon systems – think $100-million-plus per F-35 fighter – it’s easy to forget the U.S. Department of Defense is a Read more…

Synopsys Eats Ansys: Does HPC Get Indigestion?

February 8, 2024

Recently, it was announced that Synopsys is buying HPC tool developer Ansys. Started in Pittsburgh, Pa., in 1970 as Swanson Analysis Systems, Inc. (SASI) by John Swanson (and eventually renamed), Ansys serves the CAE (Computer Aided Engineering)/multiphysics engineering simulation market. Read more…

Choosing the Right GPU for LLM Inference and Training

December 11, 2023

Accelerating the training and inference processes of deep learning models is crucial for unleashing their true potential and NVIDIA GPUs have emerged as a game- Read more…

Intel’s Server and PC Chip Development Will Blur After 2025

January 15, 2024

Intel's dealing with much more than chip rivals breathing down its neck; it is simultaneously integrating a bevy of new technologies such as chiplets, artificia Read more…

Baidu Exits Quantum, Closely Following Alibaba’s Earlier Move

January 5, 2024

Reuters reported this week that Baidu, China’s giant e-commerce and services provider, is exiting the quantum computing development arena. Reuters reported � Read more…

Leading Solution Providers

Contributors

Comparing NVIDIA A100 and NVIDIA L40S: Which GPU is Ideal for AI and Graphics-Intensive Workloads?

October 30, 2023

With long lead times for the NVIDIA H100 and A100 GPUs, many organizations are looking at the new NVIDIA L40S GPU, which it’s a new GPU optimized for AI and g Read more…

Shutterstock 1179408610

Google Addresses the Mysteries of Its Hypercomputer 

December 28, 2023

When Google launched its Hypercomputer earlier this month (December 2023), the first reaction was, "Say what?" It turns out that the Hypercomputer is Google's t Read more…

AMD MI3000A

How AMD May Get Across the CUDA Moat

October 5, 2023

When discussing GenAI, the term "GPU" almost always enters the conversation and the topic often moves toward performance and access. Interestingly, the word "GPU" is assumed to mean "Nvidia" products. (As an aside, the popular Nvidia hardware used in GenAI are not technically... Read more…

Shutterstock 1606064203

Meta’s Zuckerberg Puts Its AI Future in the Hands of 600,000 GPUs

January 25, 2024

In under two minutes, Meta's CEO, Mark Zuckerberg, laid out the company's AI plans, which included a plan to build an artificial intelligence system with the eq Read more…

Google Introduces ‘Hypercomputer’ to Its AI Infrastructure

December 11, 2023

Google ran out of monikers to describe its new AI system released on December 7. Supercomputer perhaps wasn't an apt description, so it settled on Hypercomputer Read more…

China Is All In on a RISC-V Future

January 8, 2024

The state of RISC-V in China was discussed in a recent report released by the Jamestown Foundation, a Washington, D.C.-based think tank. The report, entitled "E Read more…

Intel Won’t Have a Xeon Max Chip with New Emerald Rapids CPU

December 14, 2023

As expected, Intel officially announced its 5th generation Xeon server chips codenamed Emerald Rapids at an event in New York City, where the focus was really o Read more…

IBM Quantum Summit: Two New QPUs, Upgraded Qiskit, 10-year Roadmap and More

December 4, 2023

IBM kicks off its annual Quantum Summit today and will announce a broad range of advances including its much-anticipated 1121-qubit Condor QPU, a smaller 133-qu Read more…

  • arrow
  • Click Here for More Headlines
  • arrow
HPCwire